Trials / Completed
CompletedNCT00526968
The Effects of a Novel NMDA NR2B-Subtype Selective Antagonist, EVT 101, on Brain Function
A Double Blind, Placebo Controlled Study to Investigate the Role of NMDA Receptor NR2B Subunit Selective Antagonism on Cognitive Functions and Neurophysiology in Healthy Subjects as Measured With MRI
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 19 (actual)
- Sponsor
- Evotec Neurosciences GmbH · Industry
- Sex
- Male
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to investigate the neurophysiological changes following single doses of EVT 101 using fMRI during rest and during cognitive tasks in young healthy male subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | EVT 101 | 8 mg capsule, single oral dose |
| DRUG | EVT 101 | 15 mg capsule, single oral dose |
| DRUG | placebo | Placebo capsule, single oral dose |
Timeline
- Start date
- 2007-09-01
- Primary completion
- 2007-12-01
- Completion
- 2007-12-01
- First posted
- 2007-09-10
- Last updated
- 2008-02-18
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT00526968. Inclusion in this directory is not an endorsement.